VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing

• VolitionRX outlined a partnership-led strategy to monetize its Nu.Q platform through licensing, milestones, component sales, royalties.
• Highlighted $23 million in licensing to date, revenue of $1 million in Q1 2026.
• Flagged a potential $5 million contractual milestone tied to feline use, contingent on publication of a submitted cat paper.
• Targeted multiple human-space licensing deals in 2026, with confidential talks involving more than a dozen diagnostics or liquid biopsy groups.
• Pointed to near-term clinical catalysts including DETECSEPs first patient expected in Q3, reimbursement submission preparation, initial EU sepsis sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.